⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)

Official Title: A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)

Study ID: NCT00075829

Study Description

Brief Summary: The study is designed as a Phase III, multi-center trial of tandem autologous transplants versus the strategy of autologous followed by Human Leukocyte Antigen (HLA)-matched sibling non-myeloablative allogeneic transplant. Study subjects will be biologically assigned to the appropriate arm depending on the availability of an HLA-matched sibling. There is a nested randomized phase III trial of observation versus maintenance therapy following the second autologous transplant for patients on the tandem autologous transplant arm.

Detailed Description: Multiple myeloma (MM), characterized by malignant plasma cell proliferation, bone destruction, and immunodeficiency, is a disease with a median age at diagnosis of approximately 65 years. It is responsible for about 1 percent of all cancer-related deaths in Western Countries. Conventional treatments with chemotherapy and radiation therapy are non-curative but improve quality of life and duration of survival. Attempts to cure myeloma through high-dose therapy followed by autografting or allografting have largely failed due to a combination of relapsed disease or transplant related mortality (TRM). High-dose therapy with autologous transplantation is safe and has low TRM (less than 5%), but is associated with a continuing and nearly universal risk of disease progression and relapse. Even so, autologous transplantation is superior to continued conventional chemotherapy. Recent data indicate that tandem autologous transplants are superior to a single procedure. Even with this approach, patients remain at risk of relapse and additional approaches are needed. DESIGN NARRATIVE: The overall study design is that of biologic assignment, based on the availability of an HLA-matched sibling, to one of two treatment strategies for MM patients. Patients without an HLA-matched sibling will undergo tandem autologous transplants. Patients with an HLA-matched sibling will undergo an autologous transplant followed by a non-myeloablative allogeneic transplant. In addition, the tandem autologous transplant recipients will be randomized to either observation or one year of maintenance therapy to begin following the second autologous transplant. The large number of MM patients without an HLA-matched sibling enables us to evaluate the role of maintenance therapy following tandem autologous transplants.

Eligibility

Minimum Age:

Eligible Ages: CHILD, ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

University of Alabama at Birmingham, Birmingham, Alabama, United States

City of Hope Samaritan, Phoenix, Arizona, United States

City of Hope National Medical Center, Duarte, California, United States

Scripps Clinic/Green Hospital, La Jolla, California, United States

UCSD Medical Center, La Jolla, California, United States

Stanford Hospital and Clinics, Stanford, California, United States

Colorado Blood Cancer Institute, Denver, Colorado, United States

University of Florida College of Medicine (Shands), Gainesville, Florida, United States

Emory University, Atlanta, Georgia, United States

BMT Group of Georgia/Northside Hospital, Atlanta, Georgia, United States

Loyola University, Maywood, Illinois, United States

IBMT (Indiana Blood and Marrow Transplant) at St Francis Franciscan Health, Indianapolis, Indiana, United States

Wichita CCOP, Wichita, Kansas, United States

Tufts - New England Medical Center, Boston, Massachusetts, United States

DFCI/Brigham & Women's, Boston, Massachusetts, United States

University of Michigan Medical Center, Ann Arbor, Michigan, United States

University of Minnesota, Minneapolis, Minnesota, United States

University of Nebraska Medical Center, Omaha, Nebraska, United States

Hackensack University Medical Center, Hackensack, New Jersey, United States

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Duke University Medical Center, Durham, North Carolina, United States

Jewish Hospital BMT Program, Cincinnati, Ohio, United States

University Hospitals of Cleveland/Case Western, Cleveland, Ohio, United States

University of Oklahoma Medical Center, Oklahoma City, Oklahoma, United States

Oregon Health Sciences University (A), Portland, Oregon, United States

University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States

Fox Chase - Temple University - BMT Program, Philadelphia, Pennsylvania, United States

Vanderbilt University, Nashville, Tennessee, United States

Baylor College of Medicine/The Methodist Hospital, Houston, Texas, United States

University of Texas/MD Anderson Cancer Research Center, Houston, Texas, United States

Texas Transplant Institute, San Antonio, Texas, United States

Utah BMT/Univ of Utah Med School, Salt Lake City, Utah, United States

Virginia Commonwealth University MCV Hospitals, Richmond, Virginia, United States

Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

University of Wisconsin Hospitals & Clinics, Madison, Wisconsin, United States

Medical College of Wisconsin, Milwaukee, Wisconsin, United States

Contact Details

Name: Mary Horowitz, MD

Affiliation: Center for International Blood and Marrow Transplant Research

Role: STUDY_DIRECTOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: